Business Context and Reporting Period
Company: Daré Bioscience, Inc. (DARE)
Filing Type: Form 8-K (Current Report)
Date of Report: November 20, 2019
Event: Completion of the acquisition of Microchips Biotech, Inc. ("Microchips") via a merger agreement dated November 10, 2019. Microchips, a developer of a proprietary microchip-based implantable drug delivery system, is now a wholly-owned subsidiary of Daré.
Key Financial Metrics and Transaction Details
Consideration: Daré issued approximately 3,000,000 shares of its common stock ("Closing Shares") to Microchips' effective time holders.
Regulatory Status: The issuance of Closing Shares was conducted as a private placement under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D to accredited investors; it was not registered under the Securities Act.
Financial Statements: The filing does not provide specific revenue, profit, cash flow, or debt figures for the transaction. Daré intends to provide Microchips' financial statements and pro forma financial information via an amendment to this report within the time allowed by Item 9.01 of Form 8-K.
Material Changes and Corporate Actions
- Acquisition: Microchips Biotech, Inc. merged with and into MC Merger Sub, Inc., a wholly-owned subsidiary of Daré, with Microchips surviving as a subsidiary.
- Board Appointment: Cheryl R. Blanchard, Ph.D., formerly the President and CEO of Microchips, was appointed to the Daré Board of Directors as a Class III independent director.
- Compensation: Dr. Blanchard was granted a stock option to purchase 45,000 shares of Daré common stock, vesting one-third annually over three years, subject to continued service.
Guidance, Outlook, and Risks
Outlook: The acquisition integrates Microchips' technology, specifically its lead pre-clinical stage contraceptive application utilizing levonorgestrel, into Daré's portfolio.
Risks and Contingencies: The filing notes that certain schedules and exhibits to the Merger Agreement were omitted to prevent competitive harm. The full financial impact of the acquisition is not yet quantified in this report and will be disclosed in a subsequent amendment.
Investor Verification Checklist
- Verify the exact number of Closing Shares issued and the final share price used for valuation in the subsequent amendment.
- Review the upcoming amendment to this 8-K for Microchips' historical financial statements and pro forma financial information.
- Confirm the terms of the Merger Agreement (Exhibit 2.1) regarding any contingent consideration or earn-outs not detailed in this summary.
- Monitor the integration progress of Microchips' pre-clinical contraceptive product candidate.